State of the Art in Sub-Phenotyping Midbrain Dopamine Neurons

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2024 Sep 28

PMID 39336117

Authors

Valentina Basso

Mate D Dobrossy

Lachlan H Thompson

Deniz Kirik

Heidi R Fuller

Monte A Gates

Affiliations

Soon will be listed here.

Abstract

Dopaminergic neurons in the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNpc) comprise around 75% of all dopaminergic neurons in the human brain. While both groups of dopaminergic neurons are in close proximity in the midbrain and partially overlap, development, function, and impairments in these two classes of neurons are highly diverse. The molecular and cellular mechanisms underlying these differences are not yet fully understood, but research over the past decade has highlighted the need to differentiate between these two classes of dopaminergic neurons during their development and in the mature brain. This differentiation is crucial not only for understanding fundamental circuitry formation in the brain but also for developing therapies targeted to specific dopaminergic neuron classes without affecting others. In this review, we summarize the state of the art in our understanding of the differences between the dopaminergic neurons of the VTA and the SNpc, such as anatomy, structure, morphology, output and input, electrophysiology, development, and disorders, and discuss the current technologies and methods available for studying these two classes of dopaminergic neurons, highlighting their advantages, limitations, and the necessary improvements required to achieve more-precise therapeutic interventions.

References

Pape H . Queer current and pacemaker: the hyperpolarization-activated cation current in neurons. Annu Rev Physiol. 1996; 58:299-327. DOI: 10.1146/annurev.ph.58.030196.001503. View

Ferri A, Lin W, Mavromatakis Y, Wang J, Sasaki H, Whitsett J . Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development. 2007; 134(15):2761-9. DOI: 10.1242/dev.000141. View

Khaliq Z, Bean B . Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci. 2010; 30(21):7401-13. PMC: 2892804. DOI: 10.1523/JNEUROSCI.0143-10.2010. View

Reumann D, Krauditsch C, Novatchkova M, Sozzi E, Wong S, Zabolocki M . In vitro modeling of the human dopaminergic system using spatially arranged ventral midbrain-striatum-cortex assembloids. Nat Methods. 2023; 20(12):2034-2047. PMC: 10703680. DOI: 10.1038/s41592-023-02080-x. View

Khan E, Hasan I, Haque M . Parkinson's Disease: Exploring Different Animal Model Systems. Int J Mol Sci. 2023; 24(10). PMC: 10219045. DOI: 10.3390/ijms24109088. View

Nagatsu T, Levitt M, UDENFRIEND S . TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. J Biol Chem. 1964; 239:2910-7. View

Nichterwitz S, Chen G, Benitez J, Yilmaz M, Storvall H, Cao M . Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling. Nat Commun. 2016; 7:12139. PMC: 4941116. DOI: 10.1038/ncomms12139. View

Ross C, Margolis R, Reading S, Pletnikov M, Coyle J . Neurobiology of schizophrenia. Neuron. 2006; 52(1):139-53. DOI: 10.1016/j.neuron.2006.09.015. View

Krashia P, Spoleti E, DAmelio M . The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease. Front Psychiatry. 2022; 13:1039725. PMC: 9618946. DOI: 10.3389/fpsyt.2022.1039725. View

10.

Janezic S, Threlfell S, Dodson P, Dowie M, Taylor T, Potgieter D . Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A. 2013; 110(42):E4016-25. PMC: 3801069. DOI: 10.1073/pnas.1309143110. View

11.

Sorensen A, Thompson L, Kirik D, Bjorklund A, Lindvall O, Kokaia M . Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. Eur J Neurosci. 2005; 21(10):2793-9. DOI: 10.1111/j.1460-9568.2005.04116.x. View

12.

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

13.

Luo S, Huang E . Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. Am J Pathol. 2016; 186(3):478-88. PMC: 4816693. DOI: 10.1016/j.ajpath.2015.09.023. View

14.

Glaab E, Schneider R . Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease. Neurobiol Dis. 2014; 74:1-13. DOI: 10.1016/j.nbd.2014.11.002. View

15.

Berridge K . Affective valence in the brain: modules or modes?. Nat Rev Neurosci. 2019; 20(4):225-234. PMC: 6426670. DOI: 10.1038/s41583-019-0122-8. View

16.

Perez-Costas E, Melendez-Ferro M, Roberts R . Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem. 2010; 113(2):287-302. PMC: 2929831. DOI: 10.1111/j.1471-4159.2010.06604.x. View

17.

Grimm J, Mueller A, Hefti F, Rosenthal A . Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A. 2004; 101(38):13891-6. PMC: 518849. DOI: 10.1073/pnas.0405340101. View

18.

Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P . Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023; 8(1):73. PMC: 9944326. DOI: 10.1038/s41392-023-01353-3. View

19.

Ford C, Mark G, Williams J . Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci. 2006; 26(10):2788-97. PMC: 3623681. DOI: 10.1523/JNEUROSCI.4331-05.2006. View

20.

Bayer S, Wills K, Triarhou L, Ghetti B . Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res. 1995; 105(2):191-9. DOI: 10.1007/BF00240955. View